Drugs / LSZ102
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02734615 | Jun 2016 → Sep 2021 | estrogen-receptor positive breast cancer | Novartis Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LSZ102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02734615 ↗ |
| Modality | Small molecule | — CHEMBL4076124 ↗ |
| Route | Oral | “The investigational oral SERD LSZ102” PMID 34433648 ↗ Aug 2021 |